Bavarian Nordic receives special designation from FDA

The US Food and Drug Administration has awarded the so-called Breakthrough Therapy Designation to Bavarian Nordic’s vaccine candidate for RSV prevention in adults aged 60 years or older.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Danish Bavarian Nordic has received a particularly sought-after special regulatory status from the US Food and Drug Administration (FDA), the company announces in a press release.

Vaccine candidate MVA-BN RSV, which is designed to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV) in patients 60 years or older, will now be processed by the FDA through an accelerated pathway.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs